Comparison of family caregivers’ PAT scores from other paediatric populations with this study
| Study | Population | Universal n (%) | Targeted n (%) | Clinical n (%) | Mean PAT score | 95% CI of the difference | P value |
| Verma et al (this study), n=136 | Children with medical complexity | 61 (45%) | 60 (44%) | 15 (11%) | 1.17 | ||
| Reader et al, n=13636 | Sickle cell disease | 63 (46%) | 54 (40%) | 19 (14%) | 1.15 | 0.16 to 0.20 | 0.8 |
| Sharkey et al, n=26237 | Cancer | NR | NR | NR | 1.02 | 0.00 to 0.30 | 0.05 |
| Tsumura et al, n=11738 | Cancer | NR | NR | NR | 1.45 | −0.48 to 0.0.8 | 0.006 |
| Filigno et al, n=15439 | Cystic fibrosis | 80 (52%) | 63 (41%) | 11 (7%) | 1.00 | 0.00 to 0.34 | 0.05 |
| Kapa et al, n=21740 | Craniofacial | NR | NR | NR | 0.91 | 0.10 to 0.42 | 0.001 |
| Law et al, n=23541 | Headache | 134 (57%) | 82 (35%) | 19 (8%) | 0.99 | 0.04 to 0.33 | 0.02 |
| Rocque et al, n=4042 | Brain tumour | 24 (60%) | 15 (38%) | 1 (2%) | 0.89 | 0.03 to 0.52 | 0.03 |
| Pai et al, n=14043 | Stem cell transplant | 76 (54%) | 42 (30%) | 22 (16%) | 1.14 | −0.15 to 0.21 | 0.7 |
| Schulte et al, n=9544 | Cancer | NR | NR | NR | 0.84 | 0.14 to 0.52 | <0.001 |
| Crerand et al, n=21745 | Craniofacial | 130 (60%) | 70 (32%) | 17 (8%) | 0.91 | 0.11 to 0.41 | <0.001 |
| Ernst et al n=19746 | Disorders of sexual development | 130 (66%) | 55 (28%) | 12 (6%) | 0.86 | 0.16 to 0.46 | <0.001 |
| Kazak et al, n=39447 | Cancer | 246 (62%) | 106 (27%) | 42 (11%) | 0.97 | 0.06 to 0.34 | 0.005 |
| Cousino et al, n=5648 | Heart transplant | 33 (59%) | 17 (30%) | 6 (11%) | 0.96 | 0.02 to 0.44 | 0.08 |
| Phan et al, n=10031 | Obesity | 7 (27%) | 17 (65%) | 2 (8%) | 1.20 | −0.20 to 0.14 | 0.7 |
| Woods and Ostrowski-Delahanty n=12749 | Headache | NR | NR | NR | 1.12 | −0.12 to 0.22 | 0.6 |
| Clapin et al, n=4950 | Type 1 diabetes | NR | NR | NR | 1.00 | 0.07 to 0.41 | 0.2 |
| Pierce et al, n=6751 | Cancer | 42 (63%) | 21 (31%) | 4 (6%) | 0.90 | 0.06 to 0.48 | 0.01 |
| McCarthy et al, n=8952 | Cancer | 51 (57%) | 34 (38%) | 4 (5%) | 1.00 | −0.01 to 0.35 | 0.07 |
| Sint Nicolaas et al, n=11753 | Cancer | 77 (66%) | 34 (29%) | 6 (5%) | 0.80 | 0.20 to 0.54 | <0.001 |
| Pai et al, n=4230 | Inflammatory bowel disease | 27 (64%) | 15 (36%) | 0 (0%) | 0.77 | 0.21 to 0.59 | <0.001 |
| Barrera et al, n=6722 | Cancer | 40 (60%) | 21 (31%) | 6 (9%) | NR | ||
| Hearps et al, n=3923 | Congenital heart disease | 24 (62%) | 14 (36%) | 1 (2%) | 0.81 | 0.14 to 0.58 | 0.001 |
| Karlson et al, n=21929 | Sickle cell disease | 109 (50%) | 80 (36%) | 30 (14%) | 1.12 | −0.11 to 0.21 | 0.5 |
| Pai et al, n=4524 | Kidney transplant | NR | NR | NR | 0.98 | −0.06 to 0.44 | 0.1 |
| Kazak et al, n=5033 | Cancer | 36 (72%) | 12 (24%) | 2 (4%) | 0.76 | 0.20 to 0.62 | <0.001 |
| McCarthy et al, n=22034 | Cancer | 147 (67%) | 52 (24%) | 21 (9%) | 0.93 | 0.21 to 0.51 | <0.001 |
| Alderfer et al, n=10235 | Cancer | 51 (50%) | 42 (41%) | 9 (9%) | NR | ||
| Pai et al, n=20527 | Cancer | 122 (59%) | 65 (32%) | 18 (9%) | 1.02 | −0.01 to 0.31 | 0.07 |
P values were obtained by performing independent t-tests to compare each study with the current study; p values were corrected using the Šidák correction for multiple comparisons.
.NR, not reported; PAT, Psychosocial Assessment Tool.